Alnylam Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900S3ZI14OWRJII50 - ISIN
US02043Q1076 (ALNY )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Read full profile
Fundamentals
- Net revenue
€2.10B - Gross margin
83.6% - EBIT
-€153.69M - EBIT margin
-7.3% - Net income
-€272.17M - Net margin
-13.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Tanguler Tolga | EVP, Chief Commercial Officer |
|
|
|
|
| Garg Pushkal | EVP Chief R&D |
|
|
|
|
| BONNEY MICHAEL W | N/A |
|
|
|
|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
|
|
|
|
| Greenstreet Yvonne | Chief Executive Officer |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Jefferson Shreve | June 22, 2025 | $15.00K–$50.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| James Anderson |
|
|
|
Sell |
| George Soros |
|
|
|
Buy |